...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Virology >Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK
【24h】

Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK

机译：英国专家护理下慢性丙型肝炎患者的疗效和药物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Designing services with the capacity and expertise to meet the needs of the chronic hepatitis C (CHC) population in the era of direct acting antivirals (DAAs), and widening access to such treatments, requires detailed understanding of the characteristics and healthcare needs of the existing patient population. In this retrospective analysis of data from the National HCV Research UK Biobank between March 2012 and October 2014, the characteristics of the CHC population currently under specialist care in the UK were evaluated-with specific focus upon use of medications, adverse lifestyle choices, and comorbidities. Demographic data, risk factors for CHC acquisition, HCV genotype, liver disease status, lifestyle factors, comorbidities, and medication classes were collected. Data were analyzed by history of injecting drug use (IDU), age, and severity of liver disease. A total of 6278 patients (70.5% white; median age, 52 years) from 59 UK specialist centres were included; 59.1% of patients had acquired HCV through IDU. The prevalence of adverse lifestyle factors was significantly lower in non-IDU compared with previous IDU or recent IDU patients. Depression was common in the previous (50.8%) and recent IDU (68.1%) groups, compared with 27.6% in non-IDU patients. Cirrhosis was common (23.6%), and prevalence increased with age. We describe a heterogeneous, polymorbid, and aging population of CHC patients in secondary care, and demonstrate under representation of injecting drug users within the current system. The implications of this present significant challenges to physicians and healthcare commissioners in designing services which are fit for purpose in the DAA era.
机译：设计服务与能力和专业知识，以满足直接代理抗病毒业（DAAS）时代的慢性丙型肝炎（CHC）人口的需求，并扩大对此类治疗的进程，需要详细了解现有的特征和医疗保健需求患者人口。在2012年3月至2014年3月的国家HCV研究英国BioBank的数据的回顾下，英国专家护理下的CHC人口的特征 - 在使用药物，不利的生活方式选择和合并症时，对特定的重点进行了评估。收集人口统计数据，CHC采集，HCV基因型，肝病状况，生活方式，组合和药物类别的危险因素。通过注射药物使用（IDU），年龄和肝病严重程度的历史分析了数据。共有6278名患者（白色70.5％;中位年龄，52岁）包括来自59个英国专业中心; 59.1％的患者通过IDU获得了HCV。与以前的IDU或最近的IDU患者相比，非IDU的不利生活方式因子的患病率显着降低。抑郁症在以前（50.8％）和最近的IDU（68.1％）组中常见，而非IDU患者的27.6％。肝硬化是常见的（23.6％），患病率随着年龄的增长而增加。我们描述了二次保健中的异质，多化合物和脑脊癌患者的老化患者，并在当前系统内注射吸毒者的表示下证明。对这场在设计服务的服务中对医生和医疗保健专员的影响产生了重大挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号